OriCiro's technologies will support Moderna's portfolio of therapeutics and vaccines, the companies said.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
125.1 USD | +3.01% |
|
+7.81% | +25.83% |
07-15 | Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing | MT |
07-12 | China approves CSPC Pharma's RSV vaccine for clinical trials | RE |
(Reuters) - Moderna Inc on Wednesday agreed to buy Japan-based OriCiro Genomics for $85 million to boost the U.S. drugmaker's mRNA manufacturing capabilities.
OriCiro's technologies will support Moderna's portfolio of therapeutics and vaccines, the companies said.
(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)
1st Jan change | Capi. | |
---|---|---|
+25.83% | 46.56B | |
+45.38% | 41.67B | |
+0.69% | 41.16B | |
+30.52% | 32.4B | |
+22.30% | 28.18B | |
-6.35% | 28.1B | |
+49.25% | 14.52B | |
+49.18% | 13.74B | |
+3.45% | 12.17B | |
-3.85% | 11.14B |